CAR T-Cell Developement using Xenofree Media and Gene Delivery Technology
CAR-T Therapy also called Chimeric Antigen Receptor T-cell Therapy, is a type of immunotherapy that uses specially modified T cells to target and kill cancer cells. Blood is collected from the patients and T cells are separated which are then genetically modified to express CAR in the surface . The CAR-T cells require further expansion and growth before they are infused into the patient. The optimised and high viability of CAR-T cells are essential . Through the help of our GMP certified supplier 2BScientific Limited have found a full proof high grade medium for CAR-T cell expansion. CAR-T cell therapy has shown remarkable success in treating certain types of blood cancers, such as B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), especially in cases where other treatments have failed
2BScientific Limited with support of Fujifilm and Cellecta offer a diverse range of reagents that can support the CAR-T cell therapy workflow. With Fujifilm's you will find high grade, optimised T-cell expansion medium that are serum free reducing the risk of contamination and work readily to improve potency for CAR-T therapy . While Cellecta offers a range of CRISPR services from developing CRISPR seq sgRNA libraries, including CRISPR vectors and Cas9 cell constructs and Cas9 kits to determine efficient engineering of the cells for gene knockin or knockout through in vivo or invitro process.
Fujifilm Biosciences
Fujifilm offers PRIME-XV T Cell CDM and PRIME-XV T Cell Expansion XSFM that are crucial in CAR-T cell therapy for cancer due to their specialised formulations designed to optimise T cell culture and expansion for pre-clinical use:
- PRIME-XV T Cell CDM: medium ensures consistent vigorous T cell growth, maintains T cell viability and expansion and offers efficient transduction of T cells without need for enhancers
- PRIME-XV T Cell Expansion XSFM: reduces the risk of contamination and lot-to-lot variability, optimises T cell expansion of CD4+ and CD8+ that are critical for CAR-T therapy and maintain T-cell potency, functionality and growth in the engineered CAR-T cells
Cellecta
Cellecta offers a range of effective tools and services for developing the CRISPR technology. There portfolio can help streamline the engineering of your cells with their barcode libraries, lentiviral vectors, cell constructs and kits:
- CRISP-Seq Barcoded sgRNA Libraries
- CRISPR Knockout Pooled Lentiviral sgRNA Libraries
- CRISPR sgRNA Constructs, Vectors, and Cas 9 Cell constructs for knock in or knock out cell lines
- CRISPR-Test Assay Kits offers a flow assay to accurately measure the activity of the Cas9 variant expressed by your cells
- NGS Analysis kit or services that offers quick and effective method to Amplify and sequence barcodes or sgRNA from genomic DNA samples